Report #2828986

Overview

Sex

Female

Age

Age unknown

State

—

Recovered

Unknown

Vaccinated

—

Onset

—

Days to onset

—

Hospital days

—

Symptoms (2)

Symptom narrative

administered boostrix during pregnancy; Boostrix second dose 2weeks apart form; This non-serious prospective pregnancy case was reported by a pharmacist via call center representative and described the occurrence of vaccine exposure during pregnancy in a female patient who received DTPa (Reduced antigen) (Boostrix) for prophylaxis. Co-suspect products included DTPa (Reduced antigen) (Boostrix) for prophylaxis. On an unknown date, the patient received the 2nd dose of Boostrix and the 1st dose of Boostrix. On an unknown date, an unknown time after receiving Boostrix and Boostrix, the patient experienced vaccine exposure during pregnancy (Verbatim: administered boostrix during pregnancy) and drug dose administration interval too short (Verbatim: Boostrix second dose 2weeks apart form). The outcome of the vaccine exposure during pregnancy and drug dose administration interval too short were not applicable. Pregnancy exposure: Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Exposure (Boostrix): To mother in third trimester Pregnancy Outcome: Pregnancy was ongoing Additional Information: GSK Receipt Date: 13-FEB-2025 Reporter stated that a 30 week pregnant women received Boostrix second dose 2 weeks apart from Boostrix first dose. Boostrix first dose was approximately at 28 weeks pregnancy. There was no patient information available at the moment of the call. Patient received Boostrix during pregnancy, which led to vaccine exposure during pregnancy. The patient received 2nd dose of Boostrix, earlier than the recommended interval, which led to shortening of vaccinations schedule.